1232PModel-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types. (23rd October 2018) - Zhao, X; Shen, J; Gopalakrishnan, M; Feng, Y; Schmidt, B J; Statkevich, P; Kelleher, T; Rashford, M; Ivaturi, V; Gobburu, J V S; Agrawal, S; Bello, A; et al.